PMID- 35887249
OWN - NLM
STAT- MEDLINE
DCOM- 20220728
LR  - 20220731
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 23
IP  - 14
DP  - 2022 Jul 18
TI  - Low Doses of PFOA Promote Prostate and Breast Cancer Cells Growth through 
      Different Pathways.
LID - 10.3390/ijms23147900 [doi]
LID - 7900
AB  - Endocrine Disrupting Compounds (EDCs) are found in everyday products. Widely 
      distributed throughout the environment, persistent organic pollutants (POPs) are 
      a specific class of EDCs that can accumulate in adipose tissue. Many of them 
      induce adverse effects on human health-such as obesity, fertility disorders and 
      cancers-by perturbing hormone effects. We previously identified many compounds 
      with EDC activity in the circulation of obese patients who underwent bariatric 
      surgery. Herein, we analyzed the effects of four of them (aldrin, BDE28, PFOA and 
      PCB153) on two cancer cell lines of hormone-sensitive organs (prostate and 
      breast). Each cell line was exposed to serial dilutions of EDCs from 10(-6) M to 
      10(-12) M; cytotoxicity and proliferation were monitored using the IncuCyte((R)) 
      technology. We showed that none of these EDCs induce cytotoxicity and that PFOA 
      and PCB153, only at very low doses (10(-12) M), increase the proliferation of 
      DU145 (prostate cancer) and MCF7 (breast cancer) cells, while the same effects 
      are observed with high concentrations (10(-6) M) for aldrin or BDE28. Regarding 
      the mechanistic aspects, PFOA uses two different signaling pathways between the 
      two lines (the Akt/mTORC1 and PlexinD1 in MCF7 and DU145, respectively). Thus, 
      our study demonstrates that even at picomolar (10(-12) M) concentrations PFOA and 
      PCB153 increase the proliferation of prostate and breast cancer cell lines and 
      can be considered possible carcinogens.
FAU - Charazac, Aurelie
AU  - Charazac A
AD  - Universite Cote d'Azur, INSERM U1065, C3M, Batiment Universitaire Archimed, 151 
      Route de Saint-Antoine de Ginestiere, BP 2 3194, CEDEX 3, 06204 Nice, France.
AD  - Equipe Labelisee Ligue Nationale Contre le Cancer.
FAU - Hinault, Charlotte
AU  - Hinault C
AD  - Universite Cote d'Azur, INSERM U1065, C3M, Batiment Universitaire Archimed, 151 
      Route de Saint-Antoine de Ginestiere, BP 2 3194, CEDEX 3, 06204 Nice, France.
AD  - Equipe Labelisee Ligue Nationale Contre le Cancer.
AD  - Universite Cote d'Azur, CHU, INSERM U1065, C3M, Hopital de l'Archet 2, 151 Route 
      de Saint-Antoine de Ginestiere, CS 23 079, CEDEX 3, 06202 Nice, France.
FAU - Dolfi, Bastien
AU  - Dolfi B
AD  - Universite Cote d'Azur, INSERM U1065, C3M, Batiment Universitaire Archimed, 151 
      Route de Saint-Antoine de Ginestiere, BP 2 3194, CEDEX 3, 06204 Nice, France.
AD  - Equipe Labelisee Ligue Nationale Contre le Cancer.
FAU - Hautier, Solene
AU  - Hautier S
AD  - Universite Cote d'Azur, INSERM U1065, C3M, Batiment Universitaire Archimed, 151 
      Route de Saint-Antoine de Ginestiere, BP 2 3194, CEDEX 3, 06204 Nice, France.
AD  - Equipe Labelisee Ligue Nationale Contre le Cancer.
FAU - Deconde Le Butor, Celia
AU  - Deconde Le Butor C
AD  - Universite Cote d'Azur, INSERM U1065, C3M, Batiment Universitaire Archimed, 151 
      Route de Saint-Antoine de Ginestiere, BP 2 3194, CEDEX 3, 06204 Nice, France.
AD  - Equipe Labelisee Ligue Nationale Contre le Cancer.
AD  - Universite Cote d'Azur, CHU, INSERM U1065, C3M, Hopital de l'Archet 2, 151 Route 
      de Saint-Antoine de Ginestiere, CS 23 079, CEDEX 3, 06202 Nice, France.
FAU - Bost, Frederic
AU  - Bost F
AUID- ORCID: 0000-0003-4509-4701
AD  - Universite Cote d'Azur, INSERM U1065, C3M, Batiment Universitaire Archimed, 151 
      Route de Saint-Antoine de Ginestiere, BP 2 3194, CEDEX 3, 06204 Nice, France.
AD  - Equipe Labelisee Ligue Nationale Contre le Cancer.
FAU - Chevalier, Nicolas
AU  - Chevalier N
AUID- ORCID: 0000-0001-7160-4301
AD  - Universite Cote d'Azur, INSERM U1065, C3M, Batiment Universitaire Archimed, 151 
      Route de Saint-Antoine de Ginestiere, BP 2 3194, CEDEX 3, 06204 Nice, France.
AD  - Equipe Labelisee Ligue Nationale Contre le Cancer.
AD  - Universite Cote d'Azur, CHU, INSERM U1065, C3M, Hopital de l'Archet 2, 151 Route 
      de Saint-Antoine de Ginestiere, CS 23 079, CEDEX 3, 06202 Nice, France.
LA  - eng
GR  - EST-17-086/French Agency for Food, Environmental and Occupational Health & 
      Safety/
GR  - ANR-15-IDEX-01 (ProstAdiPE Project, Academy #3)/the French government, through 
      the UCAJEDI Investments in the Future project managed by the National Research 
      Agency (ANR)/
GR  - Plan Cancer 2014-2019/ITMO/
PT  - Journal Article
DEP - 20220718
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Endocrine Disruptors)
RN  - 0 (Hormones)
RN  - OZE3CLY605 (Aldrin)
SB  - IM
MH  - Aldrin
MH  - *Breast Neoplasms
MH  - *Endocrine Disruptors/toxicity
MH  - Hormones
MH  - Humans
MH  - Male
MH  - Obesity
MH  - Prostate
PMC - PMC9318902
OTO - NOTNLM
OT  - PFOA
OT  - endocrine disrupting chemicals
OT  - hormone-dependent cancers
COIS- The authors declare no conflict of interest regarding this publication.
EDAT- 2022/07/28 06:00
MHDA- 2022/07/29 06:00
PMCR- 2022/07/18
CRDT- 2022/07/27 01:24
PHST- 2022/06/29 00:00 [received]
PHST- 2022/07/12 00:00 [revised]
PHST- 2022/07/14 00:00 [accepted]
PHST- 2022/07/27 01:24 [entrez]
PHST- 2022/07/28 06:00 [pubmed]
PHST- 2022/07/29 06:00 [medline]
PHST- 2022/07/18 00:00 [pmc-release]
AID - ijms23147900 [pii]
AID - ijms-23-07900 [pii]
AID - 10.3390/ijms23147900 [doi]
PST - epublish
SO  - Int J Mol Sci. 2022 Jul 18;23(14):7900. doi: 10.3390/ijms23147900.